BACKGROUND: Psoriasis is an inflammatory skin disease that may be associated with an adverse cardiometabolic profile including modulated plasma adiponectin and leptin levels. Whether these levels are independent of cardiometabolic risk factors, which are also prevalent in psoriasis, is not known. METHODS: A consecutive sample of 122 participants with varying degrees of psoriasis severity, and a random sample of 134 participants without psoriasis, were recruited for this case-control study. Cardiometabolic risk factors including traditional cardiovascular risk factors, waist circumference, insulin resistance, and total plasma adiponectin and leptin were measured. Total plasma adiponectin and leptin levels were compared in unadjusted and adjusted analyses by psoriasis status. RESULTS: Participants with psoriasis had mostly mild disease and were mainly on topical therapies, but still had a more adverse cardiometabolic profile compared with those without psoriasis. Furthermore, plasma adiponectin levels were significantly lower in participants with psoriasis than those without {7.13 μg/mL [interquartile range (IQR) 4.9-11.3) vs. 14.5 μg/mL (IQR 8.4-24.1); P < 0.001]}. Plasma leptin (ng/mL) levels were higher in the psoriasis group but this did not reach statistical significance [11.3 (IQR 6.4-21.8) vs. 9.8 (IQR 4.9-20.5); P = 0.07]. In multivariable modelling, plasma adiponectin levels were still negatively associated with psoriasis status after adjusting for waist size (% difference = -41.2%, P < 0.001), insulin resistance (% difference = -39.5%, P < 0.001), and both waist size and insulin resistance (% difference = -38.5%, P < 0.001). CONCLUSIONS: Plasma levels of adiponectin were lower in psoriasis, and this relationship persisted after adjusting for cardiometabolic risk factors known to decrease adiponectin levels. These findings suggest that inflammation present in psoriasis may be associated with adipose tissue dysfunction; however, direct studies of adipose tissue are needed to confirm this.
BACKGROUND:Psoriasis is an inflammatory skin disease that may be associated with an adverse cardiometabolic profile including modulated plasma adiponectin and leptin levels. Whether these levels are independent of cardiometabolic risk factors, which are also prevalent in psoriasis, is not known. METHODS: A consecutive sample of 122 participants with varying degrees of psoriasis severity, and a random sample of 134 participants without psoriasis, were recruited for this case-control study. Cardiometabolic risk factors including traditional cardiovascular risk factors, waist circumference, insulin resistance, and total plasma adiponectin and leptin were measured. Total plasma adiponectin and leptin levels were compared in unadjusted and adjusted analyses by psoriasis status. RESULTS:Participants with psoriasis had mostly mild disease and were mainly on topical therapies, but still had a more adverse cardiometabolic profile compared with those without psoriasis. Furthermore, plasma adiponectin levels were significantly lower in participants with psoriasis than those without {7.13 μg/mL [interquartile range (IQR) 4.9-11.3) vs. 14.5 μg/mL (IQR 8.4-24.1); P < 0.001]}. Plasma leptin (ng/mL) levels were higher in the psoriasis group but this did not reach statistical significance [11.3 (IQR 6.4-21.8) vs. 9.8 (IQR 4.9-20.5); P = 0.07]. In multivariable modelling, plasma adiponectin levels were still negatively associated with psoriasis status after adjusting for waist size (% difference = -41.2%, P < 0.001), insulin resistance (% difference = -39.5%, P < 0.001), and both waist size and insulin resistance (% difference = -38.5%, P < 0.001). CONCLUSIONS: Plasma levels of adiponectin were lower in psoriasis, and this relationship persisted after adjusting for cardiometabolic risk factors known to decrease adiponectin levels. These findings suggest that inflammation present in psoriasis may be associated with adipose tissue dysfunction; however, direct studies of adipose tissue are needed to confirm this.
Authors: Nehal N Mehta; YiDing Yu; Babak Saboury; Negar Foroughi; Parasuram Krishnamoorthy; Anna Raper; Amanda Baer; Jules Antigua; Abby S Van Voorhees; Drew A Torigian; Abass Alavi; Joel M Gelfand Journal: Arch Dermatol Date: 2011-05-16
Authors: Nehal N Mehta; YiDing Yu; Rebecca Pinnelas; Parasuram Krishnamoorthy; Daniel B Shin; Andrea B Troxel; Joel M Gelfand Journal: Am J Med Date: 2011-08 Impact factor: 4.965
Authors: S Shibata; Y Tada; C Hau; A Tatsuta; M Yamamoto; M Kamata; M Karakawa; Y Asano; H Mitsui; M Sugaya; T Kadono; H Saeki; N Kanda; S Sato Journal: Br J Dermatol Date: 2011-02-03 Impact factor: 9.302
Authors: Stuart P Weisberg; Daniel McCann; Manisha Desai; Michael Rosenbaum; Rudolph L Leibel; Anthony W Ferrante Journal: J Clin Invest Date: 2003-12 Impact factor: 14.808
Authors: Charlotte L Harrington; Amit K Dey; Raza Yunus; Aditya A Joshi; Nehal N Mehta Journal: Am J Physiol Heart Circ Physiol Date: 2017-03-03 Impact factor: 4.733
Authors: Joshua P Rivers; Tiffany M Powell-Wiley; Amit K Dey; Justin A Rodante; Jonathan H Chung; Aditya A Joshi; Balaji Natarajan; Aparna P Sajja; Abhishek Chaturvedi; Anshuma Rana; Charlotte L Harrington; Heather L Teague; Benjamin N Lockshin; Mark A Ahlman; Jianhua Yao; Martin P Playford; Joel M Gelfand; Nehal N Mehta Journal: JACC Cardiovasc Imaging Date: 2017-10-18
Authors: Simona Vachatova; Ctirad Andrys; Jan Krejsek; Miloslav Salavec; Karel Ettler; Vit Rehacek; Eva Cermakova; Andrea Malkova; Zdenek Fiala; Lenka Borska Journal: J Immunol Res Date: 2016-12-21 Impact factor: 4.818
Authors: Shawn Rose; Elena Stansky; Pradeep K Dagur; Leigh Samsel; Elizabeth Weiner; Amir Jahanshad; Julia Doveikis; Haley B Naik; Martin P Playford; J Philip McCoy; Nehal N Mehta Journal: J Transl Med Date: 2014-09-16 Impact factor: 5.531
Authors: Wynnis L Tom; Martin P Playford; Shehla Admani; Balaji Natarajan; Aditya A Joshi; Lawrence F Eichenfield; Nehal N Mehta Journal: J Invest Dermatol Date: 2016-01 Impact factor: 8.551